Accord Healthcare, Inc. has announced the launch of Clomiphene tablets, the generic version of CLOMID® (clomiphene citrate), aimed at addressing ovulatory dysfunction in women seeking to conceive. This development, revealed on December 2, 2025, bolsters Accord Healthcare’s commitment to expanding its women’s health portfolio and enhancing access to affordable treatment options.
The introduction of Clomiphene tablets aligns with Accord Healthcare’s mission to provide patients and healthcare providers with effective solutions for managing women’s health needs. Clomiphene citrate is specifically indicated for women who experience difficulties with ovulation, a common barrier when trying to achieve pregnancy.
Commitment to Women’s Health
Chrys Kokino, President of Accord Healthcare North America, emphasized the company’s dedication to delivering high-quality, essential medicines. “Our primary focus will always be to provide access to high quality, essential medicines for all patients and ensure a positive patient experience,” Kokino stated. The launch of Accord Clomiphene tablets represents another option for women who may require this medication as part of their fertility treatments.
Accord Healthcare’s expansion into this area reflects its ongoing commitment to advancing healthcare accessibility. By introducing this product, the company aims to support patients and healthcare providers alike in navigating the challenges associated with women’s reproductive health.
Safety Information and Side Effects
While Clomiphene citrate serves as a valuable treatment option, patients are advised to be aware of important safety information. Clomiphene should not be taken by individuals who have a known hypersensitivity to the drug or its ingredients, are pregnant, or suffer from certain medical conditions such as liver disease or uncontrolled thyroid dysfunction.
The medication can lead to serious side effects, including potential visual disturbances and ovarian hyperstimulation syndrome (OHSS), which can escalate quickly and pose significant health risks. Common side effects may include enlarged ovaries, hot flashes, abdominal discomfort, nausea, and breast tenderness.
Patients are encouraged to consult their healthcare provider for further information and to review the product insert for a comprehensive understanding of safety and potential side effects.
Accord Healthcare, a subsidiary of Intas Pharmaceuticals, is headquartered in Raleigh, North Carolina. The company is recognized for its commitment to improving access to essential medicines and providing innovative solutions for healthcare challenges. With a presence in 85 countries, Accord Healthcare continues to focus on enhancing the pharmaceutical experience for both healthcare providers and patients.
For additional details about the Clomiphene tablets or to learn more about Accord Healthcare’s offerings, visit the company’s official website.
